1. Home
  2. TRMD vs LQDA Comparison

TRMD vs LQDA Comparison

Compare TRMD & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TORM plc

TRMD

TORM plc

HOLD

Current Price

$20.50

Market Cap

2.3B

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$34.26

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRMD
LQDA
Founded
1889
2004
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.5B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
TRMD
LQDA
Price
$20.50
$34.26
Analyst Decision
Buy
Strong Buy
Analyst Count
1
10
Target Price
$23.00
$37.40
AVG Volume (30 Days)
515.6K
1.7M
Earning Date
11-06-2025
11-03-2025
Dividend Yield
9.85%
N/A
EPS Growth
N/A
N/A
EPS
2.76
N/A
Revenue
$1,292,300,000.00
$69,216,000.00
Revenue This Year
N/A
$904.79
Revenue Next Year
N/A
$188.25
P/E Ratio
$7.57
N/A
Revenue Growth
N/A
343.41
52 Week Low
$13.60
$10.37
52 Week High
$23.67
$35.54

Technical Indicators

Market Signals
Indicator
TRMD
LQDA
Relative Strength Index (RSI) 37.23 64.53
Support Level $20.35 $32.11
Resistance Level $20.91 $35.54
Average True Range (ATR) 0.38 1.55
MACD -0.12 -0.10
Stochastic Oscillator 12.74 76.90

Price Performance

Historical Comparison
TRMD
LQDA

About TRMD TORM plc

TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Engineering segment. The company derives maximum revenue from Tanker segment.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: